These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 31099410)

  • 1. Non-alcoholic steatohepatitis, but not simple steatosis, disturbs the functional homogeneity of the liver - a human galactose positron emission tomography study.
    Eriksen PL; Thomsen KL; Larsen LP; Grønbaek H; Vilstrup H; Sørensen M
    Aliment Pharmacol Ther; 2019 Jul; 50(1):84-92. PubMed ID: 31099410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of histologic, imaging, and artificial intelligence features in NAFLD patients, derived from Gd-EOB-DTPA-enhanced MRI: a proof-of-concept study.
    Bastati N; Perkonigg M; Sobotka D; Poetter-Lang S; Fragner R; Beer A; Messner A; Watzenboeck M; Pochepnia S; Kittinger J; Herold A; Kristic A; Hodge JC; Traussnig S; Trauner M; Ba-Ssalamah A; Langs G
    Eur Radiol; 2023 Nov; 33(11):7729-7743. PubMed ID: 37358613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic Alanine Differentiates Nonalcoholic Steatohepatitis From Simple Steatosis in Humans and Mice: A Proton MR Spectroscopy Study With Long Echo Time.
    Kim TH; Jun HY; Kim KJ; Lee YH; Lee MS; Choi KH; Yun KJ; Jeong YY; Jun CH; Cho EY; Yoon KH
    J Magn Reson Imaging; 2017 Nov; 46(5):1298-1310. PubMed ID: 28225569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experimental non-alcoholic fatty liver disease causes regional liver functional deficits as measured by the capacity for galactose metabolism while whole liver function is preserved.
    Eriksen PL; Thomsen KL; Hamilton-Dutoit S; Vilstrup H; Sørensen M
    BMC Gastroenterol; 2022 Dec; 22(1):541. PubMed ID: 36575375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The feasibility of T2 mapping in the assessment of hepatic steatosis, inflammation, and fibrosis in patients with non-alcoholic fatty liver disease: a preliminary study.
    Idilman IS; Celik A; Savas B; Idilman R; Karcaaltincaba M
    Clin Radiol; 2021 Sep; 76(9):709.e13-709.e18. PubMed ID: 34266657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiparametric MR Index for the Diagnosis of Non-Alcoholic Steatohepatitis in Patients with Non-Alcoholic Fatty Liver Disease.
    Kim JW; Lee YS; Park YS; Kim BH; Lee SY; Yeon JE; Lee CH
    Sci Rep; 2020 Feb; 10(1):2671. PubMed ID: 32060386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous MR quantification of hepatic fat content, fatty acid composition, transverse relaxation time and magnetic susceptibility for the diagnosis of non-alcoholic steatohepatitis.
    Leporq B; Lambert SA; Ronot M; Vilgrain V; Van Beers BE
    NMR Biomed; 2017 Oct; 30(10):. PubMed ID: 28678410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio is linked to advanced non-alcoholic fatty liver disease lean patients.
    Ampuero J; Ranchal I; Gallego-Durán R; Pareja MJ; Del Campo JA; Pastor-Ramírez H; Rico MC; Picón R; Pastor L; García-Monzón C; Andrade R; Romero-Gómez M
    J Gastroenterol Hepatol; 2016 Sep; 31(9):1611-8. PubMed ID: 26946071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis.
    Bril F; Barb D; Lomonaco R; Lai J; Cusi K
    J Hepatol; 2020 Mar; 72(3):401-410. PubMed ID: 31589891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and risk factors for biopsy-proven non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in a prospective cohort of adult patients with gallstones.
    García-Monzón C; Vargas-Castrillón J; Porrero JL; Alonso MT; Bonachía O; Castillo MJ; Marcos A; Quirós E; Ramos B; Sánchez-Cabezudo C; Villar S; Sáez A; Rodríguez de Cía J; del Pozo E; Vega-Piris L; Soto-Fernández S; Lo Iacono O; Miquilena-Colina ME
    Liver Int; 2015 Aug; 35(8):1983-91. PubMed ID: 25708133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Agreement Between Magnetic Resonance Imaging Proton Density Fat Fraction Measurements and Pathologist-Assigned Steatosis Grades of Liver Biopsies From Adults With Nonalcoholic Steatohepatitis.
    Middleton MS; Heba ER; Hooker CA; Bashir MR; Fowler KJ; Sandrasegaran K; Brunt EM; Kleiner DE; Doo E; Van Natta ML; Lavine JE; Neuschwander-Tetri BA; Sanyal A; Loomba R; Sirlin CB;
    Gastroenterology; 2017 Sep; 153(3):753-761. PubMed ID: 28624576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Magnetic resonance imaging for the assessment of pathological hepatic findings in nonalcoholic fatty liver disease.
    Imajo K; Honda Y; Yoneda M; Saito S; Nakajima A
    J Med Ultrason (2001); 2020 Oct; 47(4):535-548. PubMed ID: 33108553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiologic evaluation of nonalcoholic fatty liver disease.
    Lee SS; Park SH
    World J Gastroenterol; 2014 Jun; 20(23):7392-402. PubMed ID: 24966609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of 1-deoxy-sphingolipids with steatosis but not steatohepatitis nor fibrosis in non-alcoholic fatty liver disease.
    Weyler J; Verrijken A; Hornemann T; Vonghia L; Dirinck E; von Eckardstein A; Vanwolleghem T; Michielsen P; Peiffer F; Driessen A; Hubens G; Staels B; Francque S; Van Gaal L
    Acta Diabetol; 2021 Mar; 58(3):319-327. PubMed ID: 33084982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association Between Magnetic Resonance Imaging-Proton Density Fat Fraction and Liver Histology Features in Patients With Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis.
    Wildman-Tobriner B; Middleton MM; Moylan CA; Rossi S; Flores O; Chang ZA; Abdelmalek MF; Sirlin CB; Bashir MR
    Gastroenterology; 2018 Nov; 155(5):1428-1435.e2. PubMed ID: 30031769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MR elastography is effective for the non-invasive evaluation of fibrosis and necroinflammatory activity in patients with nonalcoholic fatty liver disease.
    Costa-Silva L; Ferolla SM; Lima AS; Vidigal PVT; Ferrari TCA
    Eur J Radiol; 2018 Jan; 98():82-89. PubMed ID: 29279175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Noninvasive Differentiation between Hepatic Steatosis and Steatohepatitis with MR Imaging Enhanced with USPIOs in Patients with Nonalcoholic Fatty Liver Disease: A Proof-of-Concept Study.
    Smits LP; Coolen BF; Panno MD; Runge JH; Nijhof WH; Verheij J; Nieuwdorp M; Stoker J; Beuers UH; Nederveen AJ; Stroes ES
    Radiology; 2016 Mar; 278(3):782-91. PubMed ID: 26348104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-alcoholic fatty liver disease causes dissociated changes in metabolic liver functions.
    Lykke Eriksen P; Sørensen M; Grønbæk H; Hamilton-Dutoit S; Vilstrup H; Thomsen KL
    Clin Res Hepatol Gastroenterol; 2019 Oct; 43(5):551-560. PubMed ID: 30770336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver histology and diffusion-weighted MRI in children with nonalcoholic fatty liver disease: A MAGNET study.
    Manning P; Murphy P; Wang K; Hooker J; Wolfson T; Middleton MS; Newton KP; Behling C; Awai HI; Durelle J; Paiz MN; Angeles JE; De La Pena D; McCutchan JA; Schwimmer JB; Sirlin CB
    J Magn Reson Imaging; 2017 Oct; 46(4):1149-1158. PubMed ID: 28225568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD44 is a key player in non-alcoholic steatohepatitis.
    Patouraux S; Rousseau D; Bonnafous S; Lebeaupin C; Luci C; Canivet CM; Schneck AS; Bertola A; Saint-Paul MC; Iannelli A; Gugenheim J; Anty R; Tran A; Bailly-Maitre B; Gual P
    J Hepatol; 2017 Aug; 67(2):328-338. PubMed ID: 28323124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.